Hypothesis: CHIPS Act quantum computing grants → IBM Anderon / GFS spinoff as first-mover commercialization plays
Hypothesis: CHIPS Act quantum computing grants → IBM Anderon / GFS spinoff as first-mover commercialization plays
The chain
On May 21-22, 2026, the US Department of Commerce signed letters of intent for $2.013 billion in CHIPS Act incentives to nine quantum computing companies. The two largest awards are:
- IBM ($1B): New subsidiary "Anderon" — first purpose-built US quantum foundry; 300mm quantum wafers. IBM adds $1B of its own money; DOC receives minority equity.
- GlobalFoundries ($375M): New subsidiary "Quantum Technology Solutions" — quantum fab across superconducting, trapped ion, photonic, topological, and silicon spin modalities. DOC receives 1% equity in QTS.
The hypothesis: these awards catalyze the first US quantum foundry industry — equivalent to how CHIPS Act awards accelerated conventional semiconductor reshoring, but for quantum manufacturing. IBM and GFS get government capital + demand signal; QBTS (D-Wave, $100M), RGTI (Rigetti, $100M) get validated technology platforms with government backing.
Why it matters
The awards are still letters of intent (not final), but they establish:
- US government as the anchor buyer for quantum computing R&D
- IBM's Anderon as the first commercial US quantum foundry (addressable market: pharma, finance, defense, materials discovery)
- GFS's QTS as a potential eventual spinoff / separate equity play
The more speculative near-term trades are QBTS and RGTI — both surged 20%+ on announcement. The more durable play (if the thesis develops) is IBM or GFS, where quantum adds margin dollars on an existing platform.
Key data points
- NIST announcement May 21, 2026; confirmed by IBM press release (Anderon), GFS press release (QTS).
- RGTI +22%, QBTS +19% on announcement (StockTwits).
- D-Wave specifically: will issue $100M of QBTS shares to DOC — equity dilution for QBTS holders.
- Awards still require final deal completion (LOIs, not executed awards).
Tickers
| Ticker | Award | Exposure type |
|---|---|---|
| IBM (NYSE) | $1B (+ $1B own) | Large-cap anchor; Anderon is a call option on quantum foundry revenue |
| GFS (GlobalFoundries, NASDAQ) | $375M | QTS spinoff is a potential discrete equity event; GFS is already a US foundry play |
| QBTS (D-Wave, NYSE) | $100M | Pure-play quantum; +19% on LOI; dilutive (new shares issued to DOC); very speculative |
| RGTI (Rigetti Computing, NASDAQ) | $100M | Pure-play quantum; +22% on LOI; very speculative |
Cautions
- QBTS/RGTI are pre-revenue or early-revenue quantum companies with extreme volatility. The $100M grants are meaningful relative to company size but do not de-risk the commercialization timeline.
- D-Wave (QBTS) dilutes existing holders by issuing $100M of shares to DOC.
- IBM quantum revenue is currently immaterial to IBM's total (~$60B+ revenue) — this is a long-dated call option for IBM specifically.
- Final deal execution not yet complete — LOIs can fail.
What evidence would graduate this to an active thesis
- Final award execution (not just LOI) for RGTI and/or QBTS
- IBM Anderon announces first paying commercial customer for 300mm quantum wafer fab services
- GFS announces timeline or terms for QTS as a standalone entity
Related
- us-fab-capacity-bottleneck — conventional fab context
- section-232-phase-2-us-fab-premium — industrial policy context